Replimune | BiotechTV

top of page

Search

Replimune's CEO discusses last week's PD-1 refractory melanoma data and the company's plans to file for accelerated approval

Replimune's CEO discusses last week's PD-1 refractory melanoma data and the company's plans to file for accelerated approval

Replimune's CEO discusses last week's PD-1 refractory melanoma data and the company's plans to file for accelerated approval

Sushil Patel describes Replimune's ASCO and follow-on data from last week in the context of PD-1 response rates and competitor data from...

Jun 10, 2024

Modality profile: Oncolytic Immunotherapies at #ASCO23

Replimune Founder and Head of R&D Robert Coffin describes the oncolytic immunotherapy approach to cancer research.

Jun 3, 2023

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

Learn more about Allucent

bottom of page